Felodipine

Major

Felodipine Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions and increased sensitive CYP3A4 substrate ex... Details Felodipine Lenacapavir Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Felodipine Letermovir Prevymis Increased CYP3A substrate exposure Details Felodipine Lisdexamfetamine Arynta Increased dextroamphetamine or lisdexamfetamine (prodrug of dextroamphetamine) exposure and an increased risk of serotonin syndrom... Details Felodipine Lonafarnib Zokinvy Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Felodipine Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Felodipine Lumacaftor Reduced exposure to CYP3A substrate Details Felodipine Mavorixafor Xolremdi Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Felodipine Melphalan Alkeran An increased risk of severe hypotension Details Felodipine Mibefradil Severe bradycardia and hypotension Details Felodipine Mifepristone Korlym Increased CYP3A4 substrate exposure Details Felodipine Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Felodipine Morphine Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Felodipine Morphine Sulfate Liposome Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Felodipine Netupitant Increased exposure of CYP3A4 substrate Details Felodipine Nilotinib Increased exposure of either drug Details Felodipine Nirmatrelvir Increased calcium channel blocker exposure and an increased risk of hypotension Details Felodipine Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details Felodipine Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Felodipine Phenobarbital Fidoquel Reduced felodipine exposure and reduced efficacy of felodipine Details Felodipine Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Felodipine Pixantrone Increased exposure to pixantrone Details Felodipine Ponesimod Ponvory An increased risk of bradycardia and heart block Details Felodipine Posaconazole Noxafil Increased felodipine exposure and an increased posaconazole exposure Details Felodipine Primidone Mysoline Reduced felodipine exposure and reduced efficacy of felodipine Details Felodipine Ranolazine Aspruzyo Increased ranolazine exposure and an increased CYP3A4 substrate exposure Details Felodipine Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Felodipine Repotrectinib Augtyro Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details Felodipine Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Felodipine St John's Wort Reduced felodipine plasma concentrations and antihypertensive efficacy Details Felodipine Suzetrigine Journavx Reduced sensitive CYP3A substrate exposure and reduced efficacy of sensitive CYP3A substrate Details Felodipine Tacrolimus Astagraf Increased tacrolimus exposure Details Felodipine Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Felodipine Tramadol ConZip Increased traMADol exposure and reduced exposure of the active metabolite Details Felodipine Trofinetide Daybue Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Felodipine Venetoclax Venclexta Increased venetoclax exposure and an increased risk of venetoclax toxicities including the risk of tumor lysis syndrome Details Felodipine Voriconazole Vfend Increased dihydropyridine calcium channel blockers (CCBs) exposure; an increased risk of dihydropyridine CCB-related adverse react... Details Felodipine Lacosamide Injection Motpoly An increased risk of AV block, bradycardia, and ventricular tachyarrhythmia Details Felodipine Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Felodipine Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details